Identification | Back Directory | [Name]
Sodium Lifitegrast | [CAS]
1119276-80-0 | [Synonyms]
Xiidra SAR 1118-023 Lifitegrast sodium Sodium Lifitegrast LIFITEGRAST SODIUM; SAR-1118-023; SAR 1118-023; SAR1118-023; XIIDRA N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-, sodium salt (1:1) | [Molecular Formula]
C29H25Cl2N2NaO7S | [MDL Number]
MFCD33029276 | [MOL File]
1119276-80-0.mol | [Molecular Weight]
639.48 |
Hazard Information | Back Directory | [Uses]
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease[1]. | [in vivo]
Lifitegrast has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior[2]. | [IC 50]
αLβ2 | [References]
[1] Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15. DOI:10.1016/j.jtos.2016.01.001 [2] Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. DOI:10.1089/jop.2012.0102 [3] Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204. DOI:10.1167/iovs.09-5144 |
|
Company Name: |
Biorbyt Ltd.
|
Tel: |
+44 (0)1223 859 353 |
Website: |
http://www.biorbyt.com |
|